Onconova Therapeutics Valuation
| ONTXDelisted Stock | USD 1.02 0.04 3.77% |
Today, the company appears to be overvalued. Onconova Therapeutics holds a recent Real Value of $0.95 per share. The prevailing price of the company is $1.02. Our model determines the value of Onconova Therapeutics from analyzing the company fundamentals such as Current Valuation of (4.56 M), return on equity of -0.84, and Shares Owned By Insiders of 0.77 % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Onconova Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Onconova Therapeutics is based on 3 months time horizon. Increasing Onconova Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Onconova Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Onconova Stock. However, Onconova Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.02 | Real 0.95 | Hype 1.02 | Naive 1.04 |
The intrinsic value of Onconova Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Onconova Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Onconova Therapeutics helps investors to forecast how Onconova stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Onconova Therapeutics more accurately as focusing exclusively on Onconova Therapeutics' fundamentals will not take into account other important factors: Onconova Therapeutics Total Value Analysis
Onconova Therapeutics is now anticipated to have valuation of (4.56 M) with market capitalization of 20.9 M, debt of 0, and cash on hands of 46.53 M. The negative valuation of Onconova Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Onconova Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(4.56 M) | 20.9 M | 0 | 46.53 M |
Onconova Therapeutics Investor Information
The company has price-to-book ratio of 1.43. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Onconova Therapeutics recorded a loss per share of 0.96. The entity last dividend was issued on the 26th of September 2018. The firm had 1:15 split on the 21st of May 2021. Based on the key indicators related to Onconova Therapeutics' liquidity, profitability, solvency, and operating efficiency, Onconova Therapeutics is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Onconova Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Onconova Therapeutics has an asset utilization ratio of 1.0 percent. This suggests that the Company is making $0.009963 for each dollar of assets. An increasing asset utilization means that Onconova Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Onconova Therapeutics Ownership Allocation
Onconova Therapeutics owns a total of 21 Million outstanding shares. Roughly 91.28 pct. of Onconova Therapeutics outstanding shares are held by general public with 0.77 % owned by insiders and only 7.95 (%) by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Onconova Therapeutics Profitability Analysis
The company reported the previous year's revenue of 226 B. Net Loss for the year was (18.95 T) with profit before overhead, payroll, taxes, and interest of 226 K.About Onconova Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Onconova Therapeutics. We calculate exposure to Onconova Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Onconova Therapeutics's related companies.Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania. Onconova Therapeutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people.
Onconova Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 21 T |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Other Consideration for investing in Onconova Stock
If you are still planning to invest in Onconova Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Onconova Therapeutics' history and understand the potential risks before investing.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |